Is rituximab one for all ages and each sex?

Abstract

In this issue of Blood, Pfreundschuh et al report that young males treated with rituximab-based immunochemotherapy in contrast to elderly males benefit as much as females from rituximab immunochemotherapy and patients with more rapid rituximab clearance have reduced therapeutic benefit. © 2014 by The American Society of Hematology.